CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases.MedComm · 2026
   Review
2. Proteomic ratio reveals subtype-specific genetic mechanisms and therapeutic targets in osteoarthritis.Clinical proteomics · 2025
   Article
3. Development of a Robust Consensus Modeling Approach for Identifying Cellular and Media Metabolites Predictive of Mesenchymal Stromal Cell Potency.Stem cells (Dayton, Ohio) · 2023
   Article
4. Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives.Frontiers in immunology · 2021
   Review
5. CD157 and Brain Immune System in (Patho)physiological Conditions: Focus on Brain Plasticity.Frontiers in immunology · 2020
   Review

Corrections and comments

• Comment on
  CD157 Marks Tissue-Resident Endothelial Stem Cells with Homeostatic and Regenerative Properties.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.